Abbott Reports 12-Month Positive Results From VOLT-AF IDE Study, Shares Rise 0.60%

Abbott has announced positive 12-month results from its VOLT-AF IDE study, demonstrating the strong safety and efficacy of its minimally invasive therapies to treat atrial fibrillation. The findings reinforce the long-term safety and performance of the Volt Pulsed Field Ablation System, which secured FDA approval and CE Mark in Europe last year. Commercial cases have begun in the U.S. and expansion in Europe continues. Abbott shares are up 0.60% to $109.75.